Moreover, the 36-month beta value for EXAS is 0.98. Analysts have varying opinions on the stock, with 18 analysts rating it as a “buy,” 5 as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for EXAS is 185.74M and currently, short sellers hold a 5.74% of that float. On June 25, 2025, EXAS’s average trading volume was 2.87M shares.
EXAS) stock’s latest price update
Exact Sciences Corp (NASDAQ: EXAS) has experienced a rise in its stock price by 2391481 compared to its previous closing price of 52.54. However, the company has seen a fall of -4.00% in its stock price over the last five trading days. zacks.com reported 2025-06-24 that Investors interested in Medical – Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
EXAS’s Market Performance
Exact Sciences Corp (EXAS) has experienced a -4.00% fall in stock performance for the past week, with a -9.40% drop in the past month, and a 8.66% rise in the past quarter. The volatility ratio for the week is 1.62%, and the volatility levels for the past 30 days are at 1.58% for EXAS.. The simple moving average for the past 20 days is -6.35% for EXAS’s stock, with a -8.22% simple moving average for the past 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with Mizuho repeating the rating for EXAS by listing it as a “Outperform.” The predicted price for EXAS in the upcoming period, according to Mizuho is $60 based on the research report published on April 10, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $52. The rating they have provided for EXAS stocks is “Sector Perform” according to the report published on March 13th, 2025.
Barclays gave a rating of “Overweight” to EXAS, setting the target price at $70 in the report published on January 23rd of the current year.
EXAS Trading at -1.26% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.74% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Zanotti Katherine S, who sale 3,207 shares at the price of $53.20 back on Jun 13 ’25. After this action, Zanotti Katherine S now owns 72,759 shares of Exact Sciences Corp, valued at $170,612 using the latest closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.68 for the gross margin
The net margin for Exact Sciences Corp stands at -0.36. The total capital return value is set at -0.2. Equity return is now at value -36.89, with -16.87 for asset returns.
Based on Exact Sciences Corp (EXAS), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.13. The debt to equity ratio resting at 1.05. The interest coverage ratio of the stock is -57.46.
Currently, EBITDA for the company is -788.73 million with net debt to EBITDA at -2.56. When we switch over and look at the enterprise to sales, we see a ratio of 4.18. The receivables turnover for the company is 10.11for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
To wrap up, the performance of Exact Sciences Corp (EXAS) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
